Dovitinib Free Base/CHIR-258/TKI-258

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
1 mg	In-stock	$36.00	Visible after login	- +
5 mg	In-stock	$56.00	Visible after login	- +
10 mg	In-stock	$108.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

1 mg

In-stock

$36.00

Visible after login

- +

5 mg

In-stock

$56.00

Visible after login

- +

10 mg

In-stock

$108.00

Visible after login

- +

Product Overview

Product Name	Dovitinib Free Base/CHIR-258/TKI-258
CAS	405169-16-6
Formula	C21H21FN6O
MW	392.43
Appearance	Light yellow to green yellow
Storage condition	Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).

Product details

Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.

Related literature

Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.

PMID: 22027573 DOI: 10.1016/j.jhep.2011.09.017

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

PMID: 15598814 DOI: 10.1182/blood-2004-10-3913

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.

PMID: 27025387 PMCID: PMC4870186 DOI: 10.14348/molcells.2016.2300

Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.

PMID: 27025387 PMCID: PMC4870186 DOI: 10.14348/molcells.2016.2300